Circulating tumor DNA for personalized lung cancer monitoring

BMC Medicine

Commentary

Clare Fiala¹  Eleftherios P. Diamandis² 

[1] Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 60 Murray St. Box 32, Floor 6, Rm L6-201, MST 3L9, Toronto, ON, Canada;Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 60 Murray St. Box 32, Floor 6, Rm L6-201, MST 3L9, Toronto, ON, Canada;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada;Department of Clinical Biochemistry, University Health Network, 60 Murray St. Box 32, Floor 6, Rm L6-201, MST 3L9, Toronto, ON, Canada;

关键词: Circulating tumor DNA;    Cancer monitoring;    Liquid biopsy;    Cancer biomarkers;    Cancer screening;    Lung cancer;   

DOI  :  10.1186/s12916-017-0921-6

 received in 2017-07-21, accepted in 2017-08-01,  发布年份 2017

来源: Springer

【 摘 要 】

Advances in deep sequencing technology have led to developments in personalized medicine. Here, we describe the implications of a recent investigation that sequenced ctDNA from the plasma of non-small cell lung cancer patients to develop personalized ctDNA tests. These ‘liquid biopsies’ have shown promise in monitoring tumor growth and response to treatment, providing a timely overview of mutations present in the tumor. We discuss the advantages of this budding approach, as well as its challenges and drawbacks, while also providing areas for further investigation and an outlook for the future.

【 授权许可】

CC BY   
© The Author(s). 2017